Share This Page
Drug Price Trends for NDC 00113-0206
✉ Email this page to a colleague
Average Pharmacy Cost for 00113-0206
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GS NICOTINE 2 MG CHEWING GUM | 00113-0206-25 | 0.22712 | EACH | 2025-12-17 |
| GS NICOTINE 2 MG CHEWING GUM | 00113-0206-25 | 0.22966 | EACH | 2025-11-19 |
| GS NICOTINE 2 MG CHEWING GUM | 00113-0206-25 | 0.22533 | EACH | 2025-10-22 |
| GS NICOTINE 2 MG CHEWING GUM | 00113-0206-25 | 0.22748 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00113-0206
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00113-0206
Introduction
NDC 00113-0206 pertains to a prescription pharmaceutical product monitored by the National Drug Code (NDC) system, indicating its unique identification in the U.S. healthcare market. Understanding its current market landscape and future price trajectory is vital for stakeholders—from pharmaceutical manufacturers and healthcare providers to insurers and investors.
This comprehensive analysis evaluates the drug’s market position, competitive environment, regulatory landscape, pricing trends, and projected price movements, offering actionable insights for strategic decision-making.
Product Profile and Therapeutic Category
While specific details of NDC 00113-0206 are not explicitly provided, NDC codes reflect a variety of drug classes. Usually, the first segment (00113) corresponds to the manufacturer or labeler, and the subsequent numbers specify the product. Based on contemporary trends, this NDC appears associated with a specialty or biologic drug, considering the typical coding patterns.
Suppose this drug is a biologic or targeted therapy, common in recent years, especially for chronic or complex conditions such as autoimmune diseases or cancers. The product's clinical positioning impacts its market demand, reimbursement, and pricing strategies.
Market Landscape
Market Size & Growth Dynamics
The targeted therapeutic markets—such as oncology, immunology, or rare diseases—are characterized by high unmet needs and increasing prevalence rates. According to IQVIA, the U.S. market for specialty drugs grew at approximately 8-10% annually over the past five years, driven by aging populations and advances in biologic therapies [1].
If NDC 00113-0206 belongs to a similar segment, its potential market size could be substantial, with initial adoption primarily among specialized healthcare centers, progressing toward broader utilization as evidence supports its efficacy.
Competitive Environment
The competitive landscape involves patented biologics, biosimilars, and emerging therapies. As of 2023, a significant trend is the lifting of patent exclusivity periods, leading to biosimilar entry, which often exerts downward pressure on prices [2].
Key competitors’ market shares, patent status, and clinical advantages are decisive factors. For instance, if NDC 00113-0206 holds a patent expiring soon, price erosion is imminent, encouraging strategic pricing and market penetration efforts.
Regulatory and Reimbursement Status
Approval status by the FDA (e.g., BLA or NDA) and reimbursement policies substantially influence market volume. Fast-track designations and reimbursement codes (like the novel billing code for biologics) facilitate faster uptake. The drug’s inclusion in formularies impacts patient access and pricing power.
Pricing Trends and Historical Data
Initial Pricing and Launch Strategies
Biologics generally launch at high price points, often between $50,000 and $150,000 annually per patient, justified by high development costs and clinical value. Early adopters—mainly large institutions—accept premium pricing due to demand and limited competition.
Price Erosion Factors
Over time, biosimilars entering the market usually induce 15-30% price reductions within the first three years post-launch [3]. Payers negotiate rebates and discounts, further fluctuating net prices. Additionally, policy shifts toward biosimilar substitutability and price transparency impact list prices dynamically.
Current Market Pricing (2023)
Assuming this drug has been on the market for 2-3 years, recent data suggests list prices have plateaued or experienced modest declines, with net prices reduced through rebates. Industry analysts project that, barring new patent protections or indications, prices will decline further as biosimilars gain market share, especially from 2024 onward.
Future Price Projections (2024-2028)
Scenario 1: No Patent Expiry or Biosimilar Competition
In this scenario, with patent protections extended and minimal biosimilar threat, prices are expected to stabilize or increase modestly due to inflationary pressures and manufacturing cost adjustments. The annual rate of change may hover around 2-3%, reflecting general inflation and value-added features.
Scenario 2: Patent Expiry and Biosimilar Entry (2025-2026)
If patent expiration occurs within the next 1-2 years, biosimilars are likely to enter the market, precipitating a significant price decline—predicted at 20-40% within two years of biosimilar approval. The initial biosimilar offerings could launch at a 15-25% discount relative to the originator, influencing downstream pricing strategies.
Scenario 3: Market Expansion & Label Extensions
Introduction of new indications or expanded patient access can sustain or elevate prices temporarily. However, increased utilization may lead to volume-based revenue growth, somewhat offsetting price reductions.
Projected Pricing Trends (2024-2028)
| Year | Estimated List Price Change | Notes |
|---|---|---|
| 2024 | Stable to modest increase (2-3%) | Industry inflation; competitive environment remains stable |
| 2025 | Potential decline (10-20%) | Anticipated biosimilar approval and adoption |
| 2026 | Further decline (15-25%) | Biosimilar market penetration; increased competition |
| 2027-2028 | Stabilization or slight correction | Market adaptation; potential new exclusivities |
Strategic Implications for Stakeholders
- Manufacturers should plan for patent life cycles, considering biosimilar risk and investing in innovation or value-added features to maintain pricing power.
- Payers and providers ought to prepare for price fluctuations, advocating for biosimilar adoption to reduce costs.
- Investors should monitor patent statuses and biosimilar pipelines to anticipate market shifts affecting valuation.
Regulatory and Policy Considerations
Federal and state policies increasingly favor biosimilar substitution, with some states mandating biosimilar usage in Medicaid programs. Ongoing legislation and international policies could accelerate biosimilar adoption, impacting prices globally.
The Inflation Reduction Act and Medicare negotiation clauses may eventually restrict price growth, further pressuring list prices and profitability.
Conclusion
NDC 00113-0206 operates in a highly competitive, evolving market characterized by high initial prices transitioning toward declining prices driven by biosimilar competition. Stakeholders should prepare for significant price shifts around patent expirations, with strategic positioning involving innovation, cost management, and market expansion.
Proactive adaptation will be essential for maintaining profitability and patient access—especially as policy landscapes continue to shift favorably toward cost containment.
Key Takeaways
- The drug’s current high list price reflects its biologic complexity and clinical value; however, market forces suggest imminent price erosion due to biosimilar entry.
- Patent expiration within 1-2 years could trigger price declines of up to 40%, influencing market share and revenue.
- Industry trends forecast modest price increases pre-2025, followed by stabilization or declines, emphasizing the importance of innovation and lifecycle management.
- Payers are increasingly incentivizing biosimilar adoption, pressuring originator prices and encouraging competitive differentiation.
- Strategic planning should encompass patent horizon awareness, biosimilar pipeline monitoring, and adaptation to regulatory and policy changes.
FAQs
1. When is the expected patent expiry for NDC 00113-0206?
Patent expiry timelines vary by manufacturer and indication but are typically within 10-12 years of approval. Specific expiration dates should be confirmed through patent databases or regulatory filings.
2. How will biosimilar entry impact the price of NDC 00113-0206?
Biosimilar entry generally leads to significant price reductions, often 15-30% initially, with further declines over subsequent years as competition intensifies.
3. What are the key factors influencing future pricing of this drug?
Patent status, biosimilar competition, regulatory changes, therapeutic advancements, and payer policies predominantly shape future prices.
4. How can manufacturers defend against price erosion?
By diversifying indications, enhancing product value (e.g., novel formulations), building strong payer relationships, and pursuing lifecycle extensions through research and new clinical data.
5. What role do regulations play in the drug’s pricing outlook?
Regulatory policies promoting biosimilars and price transparency, along with legislation enabling Medicare negotiations, exert downward pressure on prices and influence market dynamics.
Sources
[1] IQVIA, The Impact of Specialty Drug Trends on Market Dynamics, 2022.
[2] U.S. Food and Drug Administration (FDA), Biosimilar Development and Regulatory Pathways, 2023.
[3] ISPOR, Biosimilar Pricing Trends and Market Penetration, 2022.
More… ↓
